BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 98 filers reported holding BIOXCEL THERAPEUTICS INC in Q1 2023. The put-call ratio across all filers is 0.67 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $45,623 | -51.3% | 18,033 | +28.1% | 0.00% | – |
| Q2 2023 | $93,720 | +15114.3% | 14,072 | +42542.4% | 0.00% | – |
| Q1 2023 | $616 | -13.1% | 33 | 0.0% | 0.00% | – |
| Q4 2022 | $709 | -85.8% | 33 | -92.0% | 0.00% | – |
| Q3 2022 | $5,000 | -37.5% | 415 | -32.1% | 0.00% | – |
| Q2 2022 | $8,000 | -46.7% | 611 | -14.8% | 0.00% | – |
| Q1 2022 | $15,000 | -11.8% | 717 | -13.3% | 0.00% | – |
| Q4 2021 | $17,000 | -46.9% | 827 | -21.2% | 0.00% | – |
| Q3 2021 | $32,000 | -22.0% | 1,050 | -24.9% | 0.00% | – |
| Q2 2021 | $41,000 | -80.7% | 1,398 | -71.6% | 0.00% | – |
| Q1 2021 | $212,000 | -10.9% | 4,916 | -4.7% | 0.00% | -100.0% |
| Q4 2020 | $238,000 | +15.0% | 5,161 | +7.8% | 0.00% | 0.0% |
| Q3 2020 | $207,000 | +66.9% | 4,789 | +105.0% | 0.00% | – |
| Q2 2020 | $124,000 | +82.4% | 2,336 | -22.9% | 0.00% | – |
| Q1 2020 | $68,000 | – | 3,028 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Logos Global Management LP | 430,000 | $19,866,000 | 1.70% |
| APIS CAPITAL ADVISORS, LLC | 20,000 | $924,000 | 0.89% |
| Avidity Partners Management LP | 547,000 | $25,271,000 | 0.82% |
| Knoll Capital Management, LLC | 20,000 | $924,000 | 0.63% |
| Artemis Investment Management LLP | 1,013,448 | $46,839,000 | 0.49% |
| AlphaCentric Advisors LLC | 25,000 | $1,155,000 | 0.48% |
| First Light Asset Management, LLC | 94,202 | $4,352,000 | 0.32% |
| Ikarian Capital, LLC | 150,000 | $6,930,000 | 0.31% |
| Longitude (Cayman) Ltd. | 8,000 | $370,000 | 0.18% |
| AllSquare Wealth Management LLC | 5,490 | $254,000 | 0.17% |